Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07321886 · ClinicalTrials.gov registry record · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,980
- Enrollment target
- 20
- Study locations
NCT07321886 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,980 participants, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (142% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT07321886, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,980 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eloralintide
Study Locations (20)
California
- Neighborhood Healthcare Institute of Health - Escondido
- Ark Clinical Research - Fountain Valley - Fountain Valley
- Desert Oasis Healthcare Medical Group - Palm Springs
- Peninsula Research Associates - Rolling Hills Estates
- Care Access - Sacramento - Sacramento
- Southern California Clinical Research - Santa Ana
- University Clinical Investigators, Inc. - Tustin
Florida
- JEM Research Institute - Atlantis
- BioMed Research & Medical Center - Miami
- Adult Medicine of Lake County, Inc. - Mt. Dora
- American Research Centers of Florida - Pembroke Pines
- AHF Pensacola - Pensacola
- IMA Clinical Research St. Petersburg - St. Petersburg
Georgia
- Teak Research Consults - Dunwoody - Dunwoody
- Teak Research Consults - Lawrenceville
- Clinical Research Atlanta - Stockbridge
Alabama
- MFA Clinical Research - Tuscaloosa
Arizona
- Headlands Research - Scottsdale - Scottsdale
Connecticut
- Chase Medical Research, LLC - Waterbury
Hawaii
- East-West Medical Research Institute - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,980 participants |
| Start Date | 2026-02-06 |
| Est. Completion | 2030-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07321886
The ClinicalTrials.gov registry entry for NCT07321886 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,980 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (142% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07321886 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07321886 about?
NCT07321886 is a clinical study titled "A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes". The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w...
What is the current status of trial NCT07321886?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,980 participants. The study started on 2026-02-06. Estimated completion is 2030-07.
What conditions does trial NCT07321886 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07321886?
The interventions under investigation include: Placebo (DRUG), Eloralintide (DRUG).
Who is sponsoring clinical trial NCT07321886?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07321886 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.